A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

• Main Authors: Madelyn Espinosa-Cotton (Author), Elana J. Fertig (Author), Laura P. Stabile (Author), Autumn Gaither-Davis (Author), Julie E. Bauman (Author), Sandra Schmitz (Author), Katherine N. Gibson-Corley (Author), Yinwen Cheng (Author), Isaac J. Jensen (Author), Vladimir P. Badovinac (Author), Douglas Laux (Author), Andrean L. Simons (Author)
• Format: Book
• Published: BMC, 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high resp...